The CD8 T cells harvested from irradiated tumour groups with or without aCSF gave the same results in the ELISpot assay, indicating that the reduction in MHCII TAMs did not substantially affect antigen presentation (Fig EV4C and D). Here, CD8A is linked to neoplasm.